- Report
- June 2024
- 220 Pages
Global
From €5051EUR$5,550USD£4,330GBP
- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 128 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 140 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- March 2024
- 87 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 37 Pages
Global
From €2412EUR$2,650USD£2,068GBP
Pentosan Polysulfate (PPS) is a hematological drug used to treat a variety of conditions, including thrombocytopenia, anemia, and hemophilia. It is a polysulfated polysaccharide derived from beechwood hemicellulose, and is used to reduce inflammation and improve blood flow. PPS is also used to treat joint pain and inflammation associated with osteoarthritis, as well as to reduce the risk of blood clots.
PPS is available in both oral and injectable forms, and is typically administered in combination with other drugs. It is generally well-tolerated, with few side effects. However, it can cause gastrointestinal upset, nausea, and headaches in some patients.
The market for PPS is growing, driven by increasing demand for hematological drugs and the growing prevalence of conditions such as thrombocytopenia, anemia, and hemophilia. The market is expected to continue to grow in the coming years, as more patients seek treatment for these conditions.
Some companies in the PPS market include Sanofi, Pfizer, and Bayer. Show Less Read more